Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Heart Disease Mortality in Cancer Survivors: A Population-Based Study in Japan.

Journal of the American Heart Association·2023

Same author

RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS.

Science advances·2023

Same author

Analysis of gut microbiome, host genetics, and plasma metabolites reveals gut microbiome-host interactions in the Japanese population.

Cell reports·2023

Same author

Comparison of surgical outcomes between iStent inject W implantation and microhook ab interno trabeculotomy in combination with phacoemulsification in primary open-angle glaucoma patients.

Frontiers in medicine·2023

Same author

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Neurology and therapy·2023

Same author

Extracellular high molecular weight α-synuclein oligomers induce cell death by disrupting the plasma membrane.

NPJ Parkinson's disease·2023

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Gene therapy for Parkinson's disease.

Hideki Mochizuki¹

¹Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University, Hongo, Bunkyo, Tokyo, Japan. hideki@med.juntendo.ac.jp

Expert Review of Neurotherapeutics

|August 7, 2007

Summary

Parkinson's disease gene therapy shows promise. Parkin gene therapy may treat Parkinson's caused by parkin mutations and potentially alpha-synuclein gene mutations, offering new hope for patients.

Area of Science:

Molecular Biology
Virology
Neuroscience

Background:

Parkinson's disease (PD) pathology is well-defined, primarily affecting nigrostriatal dopaminergic neurons.
Genetic research has identified several genes linked to familial PD, including the parkin gene (associated with autosomal recessive juvenile parkinsonism, park2).

Purpose of the Study:

To explore the potential of parkin gene therapy for Parkinson's disease.
To investigate parkin gene therapy's efficacy in PD cases with parkin gene mutations and alpha-synuclein gene mutations.

Main Methods:

Gene transfer technologies.
Analysis of genetic mutations in Parkinson's disease.
Investigating the effects of parkin gene therapy in relevant PD models (implied).

More Related Videos

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

Main Results:

Parkin gene therapy is a viable approach for PD resulting from parkin gene mutations (autosomal recessive trait).
Preliminary evidence suggests parkin gene therapy may benefit PD patients with alpha-synuclein gene mutations.
Parkin overexpression could potentially correct anatomical degeneration in the substantia nigra and striatum.

Conclusions:

Parkin gene therapy holds significant therapeutic potential for specific forms of Parkinson's disease.
Further research may establish parkin gene therapy as a treatment for alpha-synucleinopathies.
Gene therapy represents a promising avenue for treating neurodegenerative disorders like Parkinson's disease.